Sixty years of aging cell research in one overview

A comprehensive historical overview published in a scientific journal traces how cellular senescence has changed in meaning over the past sixty years. It began with a straightforward observation: cells in a dish stop dividing at a certain point, regardless of how well you care for them. That limit is called the Hayflick limit, after the researcher who described it in the 1960s. The overview describes how the significance of that phenomenon was progressively reinterpreted.

From tumour brake to aging driver

Initially, senescence was thought to protect against cancer: a cell that stops dividing cannot become cancerous. That is partly true. But researchers later discovered that senescent cells also secrete substances that influence their surroundings. This secretory pattern is called the SASP (senescence-associated secretory phenotype). These substances can stimulate tissue repair, but also fuel chronic inflammation and damage healthy neighbouring cells. In younger people, the immune system clears senescent cells away. In older people, this clearance works less well, causing the cells to accumulate.

From phenomenon to therapy

Recent years have added two further insights. First: senescent cells are not a uniform group. Depending on the tissue, the trigger and the context, they behave differently. Second: a small industry of biotech companies has emerged developing drugs to selectively destroy senescent cells or modify their behaviour. These therapies are called senotherapeutics.

This overview is not primary research but a descriptive account. Its value lies in bringing together a fragmented field. For anyone wanting to understand longevity science, it provides a clear starting point.

Read the original article